All In Biotech

Drug Trial Radar · NCT05876312

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Participants Followed by a Phase 2a Open Label Study in Participants With PNH and Residual Anemia to Evaluate the Safety, Tolerability, PK and PD of ADX-038

Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Aug 7, 2023

Primary completion

Mar 31, 2028

Study completion Jul 31, 2028

Sponsor

Lead sponsor
ADARx Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
ADARx Australia Pty Ltd; Novotech (Australia) Pty Limited
First posted
May 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

  • ADX-038Drug

    siRNA duplex oligonucleotide

  • PlaceboDrug

    Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety in Healthy VolunteersTime frame: 365 days
  2. Safety in Paroxysmal Nocturnal Hemoglobinuria ParticipantsTime frame: 365 days

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Nucleus Network Brisbane

    Brisbane, Queensland, Australia · Completed

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Completed

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Recruiting

  • Richmond Pharmacology Ltd

    London, London, United Kingdom · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.